You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Merck
Express Scripts
Dow
AstraZeneca

Last Updated: February 17, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LDK378


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LDK378?

LDK378 is an investigational drug.

There have been 29 clinical trials for LDK378. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are thirty-four US patents protecting this investigational drug and six hundred and seventy-nine international patents.

Recent Clinical Trials for LDK378
TitleSponsorPhase
Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol)National Cancer Institute (NCI)Phase 2
A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementYonsei UniversityPhase 2
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaNational Cancer Institute (NCI)Phase 1/Phase 2

See all LDK378 clinical trials

Clinical Trial Summary for LDK378

Top disease conditions for LDK378
Top clinical trial sponsors for LDK378

See all LDK378 clinical trials

US Patents for LDK378

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LDK378   Start Trial Polycyclic inhibitor of anaplastic lymphoma kinase XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN)   Start Trial
LDK378   Start Trial Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same 2Y-CHEM, LTD. (Shanghai, CN)   Start Trial
LDK378   Start Trial Inhibitors of ACK1/TNK2 tyrosine kinase H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL)   Start Trial
LDK378   Start Trial Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LDK378

Drugname Country Document Number Estimated Expiration Related US Patent
LDK378 China 107108586 2034-09-29   Start Trial
LDK378 European Patent Office 3202765 2034-09-29   Start Trial
LDK378 Japan 2017530139 2034-09-29   Start Trial
LDK378 Japan 6554538 2034-09-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKesson
Colorcon
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.